Zoetis experienced a 11% decline in its stock price over the last week. This move occurred amidst a highly volatile market, with the S&P 500 down 12% due to escalating U.S.-China trade tensions and a broad-based sell-off in various sectors, including pharmaceuticals. While the company saw price pressures similar to those affecting pharmaceutical stocks as well as broader economic uncertainty, it should be noted that Zoetis's movement is in line with general market trends, reflecting broader investor sentiment and market fluctuations rather than company-specific factors contributing independently to the decline.

We've identified 1 warning sign with Zoetis and understanding the impact should be part of your investment process.

Uncover 9 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

The recent decline in Zoetis's stock price amidst market volatility can influence the company's narrative on revenue and earnings potential. With a reported revenue of US$9.26 billion and earnings of US$2.49 billion, analysts predict an annual growth rate of 4.6% in revenue and an increase in profit margins from 26.9% to 29.1% over the next three years. However, geopolitical tensions and foreign exchange headwinds could moderate these growth prospects. The continued investment in high-value areas like pet pain management and dermatology franchises might be crucial in driving future success, countering these broader challenges.

Over the five-year period, Zoetis has delivered a total shareholder return of 17.48%, showcasing resilience in comparison to the previous year's underperformance against the US Pharmaceuticals industry, which returned 11.5%. Analysts have set a consensus price target of US$199.99, which is 19% higher than the current share price of US$161.91. This suggests potential upside, although the stock's performance must be evaluated in light of market conditions and industry trends. With a PE ratio of 26x, Zoetis trades higher than the industry average, indicating a premium valuation largely aligned with strong growth expectations. Investors should consider how these estimates align with their assumptions and the broader economic landscape.

Explore Zoetis' analyst forecasts in our growth report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:ZTS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com